Company intelligence / Profile preview

EVE Health Group

Subiaco, Western Australia, Australia

Ownership: Private
Employees: ~3
Development stage: Other

Overview

EVE Health Group is an Australian biotech and pharma company focused on developing and commercializing pharmaceutical and nutraceutical products for women's and men's health conditions, including dysmenorrhoea, endometriosis, and erectile dysfunction. Leveraging its nano-emulsion delivery platform, the company has commercial-stage products like Dyspro and Libbo, and is advancing its pipeline through the recent acquisition of Nextract, aiming for TGA export-only registration and full ARTG listing.

Therapeutic areas: Men's HealthWomen's Health
Modalities: Small moleculeGummy formulationOral dissolving filmOral strip and chewable dosage formats
Industry: Biotech

Beyond the preview

Go deeper on EVE Health Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVE Health Group.

Explore the full profile